Patents by Inventor Tudor Oprea
Tudor Oprea has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230404977Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type I), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp. infections, especially including Entamoeba histolytica.Type: ApplicationFiled: April 24, 2023Publication date: December 21, 2023Inventors: Angela Wandinger-Ness, Laurie Hudson, Larry Sklar, Zurab Surviladze, Tudor Oprea
-
Patent number: 11672779Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type I), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp. infections, especially including Entamoeba histolytica.Type: GrantFiled: November 11, 2020Date of Patent: June 13, 2023Assignee: UNM Rainforest InnovationsInventors: Angela Wandinger-Ness, Laurie Hudson, Larry Sklar, Zurab Surviladze, Tudor Oprea
-
Publication number: 20210212989Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type 1), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp. infections, especially including Entamoeba histolytica.Type: ApplicationFiled: November 11, 2020Publication date: July 15, 2021Inventors: Angela Wandinger-Ness, Laurie Hudson, Larry Sklar, Zurab Surviladze, Tudor Oprea
-
Patent number: 10857130Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type I), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp. infections, especially including Entamoeba histolytica.Type: GrantFiled: February 28, 2017Date of Patent: December 8, 2020Assignee: UNM Rainforest InnovationsInventors: Angela Wandinger-Ness, Laurie Hudson, Larry Sklar, Zurab Surviladze, Tudor Oprea
-
Publication number: 20170182002Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type I), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp. infections, especially including Entamoeba histolytica.Type: ApplicationFiled: February 28, 2017Publication date: June 29, 2017Inventors: Angela Wandinger-Ness, Laurie Hudson, Larry Sklar, Zurab Surviladze, Tudor Oprea
-
Patent number: 9642835Abstract: The present invention relates to molecules which function as selective modulators (i.e., inhibitors and agonists, preferably inhibitors) of the Ras-homologous (Rho) family of small GTPases, in particular, Cdc42 GTPase and their use to treat diseases, for example cancers, including metastatic cancer, where Cdc42 GTPase is overexpressed or hyperactivated, genetic and acquired diseases where activation of Cdc42 GTPase plays a pivotal role (e.g., neurodegenerative diseases), rheumatoid arthritis, atherosclerosis, diabetes type I, autosomal polycystic kidney diease, cystic kidney disease, precystic kidney disease and microbial infections. Additionally, compounds according to the present invention may be used to inhibit rejection (graft host response) in transplant patients (pursuant to transplantation), to promote immunosuppression, anti-inflammatory response and to mobilize stem cell (migration) in patients in need, among others.Type: GrantFiled: April 22, 2013Date of Patent: May 9, 2017Assignees: STC.UNM, UNIVERSITY OF KANSASInventors: Angela Wandinger-Ness, Larry Sklar, Zurab Surviladze, Tudor Oprea, Laurie Hudson, Jeffrey Aube, Jennifer E. Golden, Chad E. Schroeder, Denise S. Simpson, Julica J. Noth
-
Publication number: 20150335619Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type 1), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp. infections, especially including Entamoeba histolytica.Type: ApplicationFiled: July 30, 2015Publication date: November 26, 2015Inventors: Angela Wandinger-Ness, Laurie Hudson, Larry Sklar, Zurab Surviladze, Tudor Oprea
-
Patent number: 9125899Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type 1), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp, infections, especially including Entamoeba histolytica.Type: GrantFiled: June 16, 2011Date of Patent: September 8, 2015Assignee: STC.UNMInventors: Angela-Wandinger Ness, Laurie Hudson, Larry Sklar, Zurab Surviladze, Tudor Oprea
-
Publication number: 20060148079Abstract: A method for producing an ex vivo population of human insulin-producing cells that produce insulin in response to glucose from a patient is disclosed. The population of insulin producing cells is derived from human epithelial cells by causing those epithelial cells to differentiate into insulin producing cells. In one embodiment, the epithelial cells are derived from human mesenchymal stem cells (MSCs). The MSCs can be cultured from human bone marrow. In one embodiment, a culture of epithelial cell linage is generated by cultivating a sample of human cells containing a mixed culture containing human MSCs to produce an enriched culture of MSCs having a higher concentration of MSCs than the sample; and then differentiating cells from the enriched culture into cells of the epithelial cell lineage.Type: ApplicationFiled: January 3, 2005Publication date: July 6, 2006Inventors: Virgil Paunescu, Erika Suciu, Calin Tatu, Tudor Oprea
-
Patent number: 6675136Abstract: A computer based technique for the global investigation of property spaces is described. More particularly, a technique is described for the global investigation of chemical space, with reference to drugs, using a system comprised of molecules and descriptors that allows systematic mapping of the chemical space. The technique is used to generate a map of N-dimensional chemical space that allows one to examine, in a consistent manner with existing tools, the inner relationship between various molecules. The technique therefore allows one to investigate unexplored regions of the chemical space, avoiding redundancy, generating compounds with similar chemical information content, or to focus on subsets of the chemical space that are relevant to drug-like structures, without additional errors due to extrapolation.Type: GrantFiled: January 14, 2000Date of Patent: January 6, 2004Assignee: AstraZeneca ABInventors: Johan Gottfries, Tudor Oprea